Search details
1.
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.
JTO Clin Res Rep
; 5(4): 100648, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38590729
2.
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
Lung Cancer
; 193: 107856, 2024 Jun 15.
Article
in English
| MEDLINE | ID: mdl-38889498
3.
Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
Ann Transl Med
; 11(10): 358, 2023 Aug 30.
Article
in English
| MEDLINE | ID: mdl-37675321
4.
Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference.
Clin Epigenetics
; 15(1): 36, 2023 03 02.
Article
in English
| MEDLINE | ID: mdl-36864513
5.
Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now?
Cancers (Basel)
; 15(4)2023 Feb 08.
Article
in English
| MEDLINE | ID: mdl-36831411
6.
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
JAMA Oncol
; 9(2): 261-265, 2023 02 01.
Article
in English
| MEDLINE | ID: mdl-36580285
7.
Have We Revealed the Achilles' Heel of Brigatinib? Implications on Clinical Practice.
J Thorac Oncol
; 15(7): 1100-1102, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32593441
Results
1 -
7
de 7
1
Next >
>>